The European Commission has authorized IMCIVREE (setmelanotide) for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity.

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity Rhythm Pharmaceuticals, Inc. — First therapy to be FDA-approved and EC-authorized fo… #Europe #EU #EuropeanCommission #HO #hypothalamicdysfunction #hypothalamicobesity #pediatricpatients #Pharmaceuticals #Rhythm #setmelanotide #treatmentofobesity https://www.europesays.com/europe/28266/

Rhythm gets EU approval for IMCIVREE in rare obesity Rhythm Pharmaceuticals (NASDAQ: RYTM) announced the European Commission authorized IMCIVREE (setmelanotide) for treatment of obesity and control of… #Europe #EU #acquiredhypothalamicobesity #EuropeanCommissionauthorization #EuropeanUnion #IMCIVREE #obesitytreatment #Phase3TRANSCEND #raredisease #RhythmPharmaceuticals #RYTM https://www.europesays.com/europe/28270/